Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmyriaASX:EMD 3-Year EBITDA Growth Rate is 20.60% as of Jun. 2026, which is 10% above its 10-year median of 18.80. The stock has 4 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Emyria ranks better than 67.49% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Emyria was 38.70% per year. The lowest was -13.20% per year. And the median was 18.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Emyria 3-Year EBITDA Growth Rate Related Terms
ASX:EMD vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Emyria's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emyria 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emyria's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Emyria's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.60% mean?
Emyria (ASX:EMD) has a 3-Year EBITDA Growth Rate of 20.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Emyria and its competitors. This is 10% above median its historical median of 18.80. According to the industry distribution chart, Emyria ranks #171 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 32.5%.
Is Emyria's 3-Year EBITDA Growth Rate too high?
Emyria's current 3-Year EBITDA Growth Rate of 20.60% is 10% above median its 10-year median of 18.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Emyria's value of 20.60% is 105% above this industry median. Based on the distribution chart, Emyria ranks #171 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Emyria's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #171 out of 526 companies for 3-Year EBITDA Growth Rate. This puts Emyria in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. Emyria's value of 20.60% is 105% above this benchmark. While the company's 10-year median is 18.80 vs. the industry median of 10.05, Emyria has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emyria's current 3-Year EBITDA Growth Rate of 20.60% is 105% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Emyria and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emyria's current 3-Year EBITDA Growth Rate is 20.60%, which is 10% above median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Fairly Valued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.05 — trading 4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.60%, which is 10% above median its 10-year median of 18.80 and 105% above the Healthcare Providers & Services industry median of 10.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Emyria (ASX:EMD), the current 3-Year EBITDA Growth Rate is 20.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emyria Ltd is an Australian healthcare and drug development company focused on psychedelic-assisted therapies and cannabinoid-based medicines. It operates specialist medical clinics that provide mental health and pain management services, generating clinical data from consenting patients through its proprietary software platform. This data supports its drug development programs, which include MDMA-assisted therapy for post-traumatic stress disorder and other psychedelic compounds. The company also conducts clinical trials and research collaborations with academic institutions. Emyria's revenue comes from patient consultations and treatments at its clinics, as well as from research partnerships and licensing arrangements. Its operations are primarily based in Australia, with a focus on developing and commercializing novel therapies for unmet mental health needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMD has been successfully added to your 
